ClinicalTrials.Veeva

Menu
U

University of Rochester | UR Dermatology at College Town

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

PF-04965842
Dupilumab
Omalizumab
CTP-543

Parent organization

This site is a part of University of Rochester

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 5 total trials

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

Primary Objective:To demonstrate the efficacy of dupilumab in study participants with CSU who remain symptomatic despite the use of H1 antihistamine...

Active, not recruiting
Chronic Spontaneous Urticaria
Drug: non sedating H1-antihistamine
Drug: Dupilumab SAR231893

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in a...

Active, not recruiting
Alopecia Areata
Drug: CTP-543

This is a prospective, randomized, double blind, placebo-controlled clinical trial. The study will take place at 4 sites. This trial will enroll a to...

Enrolling
Alopecia Areata
Drug: Placebo
Drug: Dupilumab

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Trial sponsors

Pfizer logo
Concert Pharmaceuticals logo
Sanofi logo
E

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems